# Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer

> **NCT02909751** · PHASE2 · COMPLETED · sponsor: **Vejle Hospital** · enrollment: 80 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Epirubicin 90 mg/m2 iv
- **DRUG:** Cyclophosphamide 600 mg/m2 iv
- **DRUG:** Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv
- **DRUG:** Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)
- **DRUG:** Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)
- **DIETARY_SUPPLEMENT:** Tocotrienol 300 mg x 3 daily

## Key facts

- **NCT ID:** NCT02909751
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-14
- **Primary completion:** 2019-01-21
- **Final completion:** 2019-01-21
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02909751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02909751, "Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02909751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*